Advanced Hepatocellular Carcinoma (HCC) Clinical Trial
Official title:
An Open-Label Phase 2 Study of WGI-0301 Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma as Second Line Therapy
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 / PD-L1 immune checkpoint inhibitors.
This study will include a two-stage design: Stage 1 (dose escalation) to determine the MTD/RP2D of WGI-0301 combined with Sorafenib. Stage 2 (dose expansion) with two different dose levels of WGI-0301 in combination with standard dose Sorafenib, or standard dose Sorafenib alone. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04985136 -
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
|
Phase 3 | |
| Recruiting |
NCT02509169 -
Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04723004 -
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
|
Phase 3 | |
| Completed |
NCT02814461 -
The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC
|
Phase 1 | |
| Not yet recruiting |
NCT04344158 -
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
|
Phase 3 | |
| Completed |
NCT02906397 -
Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)
|
Phase 1 | |
| Active, not recruiting |
NCT04523493 -
Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC
|
Phase 3 | |
| Terminated |
NCT05375604 -
A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)
|
Phase 1 | |
| Terminated |
NCT01101906 -
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
|
Phase 2 | |
| Recruiting |
NCT05862181 -
The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
|
||
| Terminated |
NCT04212221 -
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04605796 -
A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
|
Phase 2 |